PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(12.59%)
USD 0.16
(12.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 2.58 Million CAD | -58.96% |
| 2023 | 6.3 Million CAD | -48.13% |
| 2022 | 12.16 Million CAD | 104.64% |
| 2021 | 5.94 Million CAD | 1422.41% |
| 2020 | 390.43 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.91 Million CAD | -18.39% |
| 2024 Q2 | 3.57 Million CAD | -26.92% |
| 2024 Q1 | 4.88 Million CAD | -22.55% |
| 2024 Q4 | 2.58 Million CAD | -11.13% |
| 2023 Q2 | 8.09 Million CAD | -20.6% |
| 2023 Q3 | 7.57 Million CAD | -6.38% |
| 2023 Q4 | 6.3 Million CAD | -16.7% |
| 2023 Q1 | 10.19 Million CAD | -16.23% |
| 2023 FY | 6.3 Million CAD | -48.13% |
| 2022 Q4 | 12.16 Million CAD | 2.46% |
| 2022 Q3 | 11.87 Million CAD | -20.66% |
| 2022 Q2 | 14.96 Million CAD | 187.8% |
| 2022 Q1 | 5.19 Million CAD | -12.53% |
| 2022 FY | 12.16 Million CAD | 104.64% |
| 2021 Q1 | 1.6 Million CAD | 0.0% |
| 2021 FY | 5.94 Million CAD | 1422.41% |
| 2021 Q3 | 7.1 Million CAD | 566.38% |
| 2021 Q4 | 5.94 Million CAD | -16.36% |
| 2021 Q2 | 1.06 Million CAD | -33.75% |
| 2020 FY | 390.43 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -37.911% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -418.956% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -891.206% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 75.461% |
| GB Sciences, Inc. | 103.44 Thousand USD | -2403.619% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 71.061% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -14384.306% |
| Skye Bioscience, Inc. | 11.94 Million USD | 78.311% |
| Zenith Capital Corp. | 7410.00 USD | -34849.987% |
| Agentix Corp. | 261.39 Thousand USD | -890.77% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -32.255% |
| Biomind Labs Inc. | 73.81 Thousand USD | -3408.303% |
| ContraFect Corporation | 20.67 Million USD | 87.476% |
| CSL Limited | 38.02 Billion USD | 99.993% |
| CytoDyn Inc. | 11.13 Million USD | 76.744% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -236.056% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 90.732% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -438.915% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -3478.794% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -632.373% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.011% |
| SQZ Biotechnologies Company | 107.18 Million USD | 97.584% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 21.83% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 93.333% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -80.847% |
| Mesoblast Limited | 667.9 Million USD | 99.612% |
| Marizyme, Inc. | 22.01 Million USD | 88.236% |
| Genus plc | 1.02 Billion USD | 99.748% |
| Pharming Group N.V. | 462.85 Million USD | 99.44% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -313.045% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -577.643% |
| IMV Inc. | 31.33 Million USD | 91.735% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 37.535% |
| MultiCell Technologies, Inc. | 126.22 USD | -2051709.539% |
| ONE Bio Corp. | 70.08 Million USD | 96.305% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 97.985% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 92.638% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -78.749% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 91.372% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 5.7% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -276.705% |
| Alpha Cognition Inc. | 2.45 Million USD | -5.612% |
| Enzolytics Inc. | 361.7 Million USD | 99.284% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.943% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 94.571% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -304.873% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.924% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 64.129% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -3291.825% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -704.769% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -890.876% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -179.084% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -90.657% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -563.427% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -175.601% |
| Helix BioMedix, Inc. | 3.02 Million USD | 14.389% |
| EV Biologics, Inc. | 431.71 Thousand USD | -499.886% |
| Q BioMed Inc. | 3.51 Million USD | 26.332% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 95.086% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.42% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 82.213% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 0.515% |
| HST Global, Inc. | 1526.00 USD | -169611.271% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -112012.294% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -162.134% |
| Halberd Corporation | 10.13 Thousand USD | -25463.064% |
| Resverlogix Corp. | 8.11 Million USD | 68.086% |
| Cell Source, Inc. | 195.17 Thousand USD | -1226.936% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -11268.219% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | 64.894% |
| Ember Therapeutics, Inc. | 184.00 USD | -1407396.739% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -4060.445% |
| Kadimastem Ltd | 2.3 Million USD | -12.4% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -2607.375% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -4436.018% |
| LadRx Corporation | 2.3 Million USD | -12.215% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -632.373% |
| Affymax, Inc. | 7.44 Million USD | 65.205% |
| Itoco Inc. | 1.4 Million USD | -84.976% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -2343.202% |
| Mobile Lads Corp. | 52.00 USD | -4980273.077% |
| International Stem Cell Corporation | 5.39 Million USD | 51.952% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1781.598% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1711.399% |
| Qrons Inc. | 420.00 USD | -616517.619% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -571.852% |
| SYBLEU INC | 330.46 Thousand USD | -683.675% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -369.064% |
| Rebus Holdings, Inc. | 5000.00 USD | -51695.88% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -532.549% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 82.737% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 84.379% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -3178.22% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -199.51% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 65.548% |
| Neutra Corp. | 2851.00 USD | -90738.092% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 92.008% |
| PureTech Health plc | 693.97 Million USD | 99.627% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 67.913% |
| IXICO plc | 15.84 Million USD | 83.654% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 68.73% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.494% |
| CSL Limited | 38.02 Billion USD | 99.993% |
| Cellectis S.A. | 333.99 Million USD | 99.225% |